The effect of atorvastatin on macular pigment optical density: experimental study
Article Sidebar
Main Article Content
Abstract
Introduction: Low-density lipoprotein (LDL)- and high-density lipoprotein (HDL) cholesterol are serum lipoproteins involved in the transportation of lutein and zeaxanthin to the retina to serve as macular pigments (MPs). Atorvastatin, a serum cholesterol-lowering agent, can affect the MP distribution and reduce macular pigment optical density (MPOD). MPOD is one of the best indicators of retinal diseases such as age-related macular degeneration.
Objective: To study the effect of atorvastatin on the level of MPOD in people taking atorvastatin 10 mg for more than 6 months.
Methodology: An experimental study was conducted on 44 Asian men and women, aged between 30 and 60 years and residing in Thailand, who were recruited and divided into two equal groups. The first group was currently taking atorvastatin 10 mg for at least 6 months, whereas the control group did not receive atorvastatin. MPOD was measured in all participants using the macular pigment screener-II. Participants were required to sign an informed consent form and complete questionnaires regarding various factors that may influence the MPOD. Data were analyzed using the Kolmogorov–Smirnov test and t-test to compare the MPOD between groups.
Results: The mean MPOD of the experiment group was 0.3295 ± 0.1311 DU, whereas that of the control group was 0.4686 ± 0.1491 DU. The mean MPOD of the experimental group was significantly lower than that of the control group (p-value = 0.002).
Conclusion: Patients taking atorvastatin had a lower MPOD than those who did not.
Article Details
JHSAM publishes all articles in full open access, meaning unlimited use and reuse of articles with appropriate credit to the authors.
All our articles are published under a Creative Commons "CC-BY-NC-ND 4.0". License which permits use, distribution and reproduction in any medium,
provided that the original work is properly cited and is used for noncommercial purposes.
References
Narindrarangkura P, Bosl W, Rangsin R, Hatthachote P. Prevalence of dyslipidemia associated with complications in diabetic patients: a nationwide study in Thailand. Lipids Health Dis. 2019:18(90):1-8.
National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation 2002;106:3143–421.
Benjamin EJ, Virani SS, Callaway CW, Chamberlain AM, Chang AR, Cheng S, et al. Heart disease and stroke statistics-2018 update: a report from the American Heart Association. Circulation. 2018;137(12):e67-e492.
Sniderman AD, Tsimikas S, Fazio S. The severe hypercholesterolemia phenotype: clinical diagnosis, management, and emerging therapies. J Am Coll Cardiol. 2014:1935-47.
Lepor NE, Vogel RE, National Cholesterol Education Program Adult Treatment Panel III. Summary of the third report of the National Cholesterol Education Program Adult Treatment Panel III. Rev Cardiovasc Med 2001;2:160–5.
Pekkanen J, Nissinen A, Punsar S, Karvonen M. Short- and long-term association of serum cholesterol with mortality: the 25-year follow-up of the Finnish cohorts of the seven countries study. Am J Epidemiol. 1992;135(11):1251-8.
Eckel RH, Jakicic JM, Ard JD, de Jesus JM, Houston Miller N, Hubbard VS, et al. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;63:2960–84.
Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 Suppl 2):S1-45.
Adams SP, Tsang M, Wright JM. Lipid-lowering efficacy of atorvastatin. Cochrane Database Syst Rev. 2015:CD008226.
Farnier M, Portal JJ, Maigret P. Efficacy of atorvastatin compared with simvastatin in patients with hypercholesterolemia. J Cardiovasc Pharmacol Ther. 2000;5(1):27-32.
Beatty S, Boulton M, Henson D, Koh H, Murray I. Macular pigment and age related macular degeneration. Br J Ophthalmol. 1999;83(7):867-77.
Snodderly DM, Auran J, Delori F. The macular pigment. II. Spatial distribution in primate retinas. Investig Ophthalmol Vis Sci. 1984;25(6):674-85.
Trieschmann M, Van Kuijk F, Alexander R, Hermans P, Luthert P, Bird A, et al. Macular pigment in the human retina: histological evaluation of localization and distribution. Eye. 2008;22(1):132-7.
Landrum JT, Bone RA, Kilburn MD. The macular pigment: a possible role in protection from age-related macular degeneration. Adv Pharmacol. 1996;38:537-56.
SanGiovanni J, Chew E, Clemons T, Ferris 3rd F, Gensler G, Lindblad A, et al. The relationship of dietary carotenoid and vitamin A, E, and C intake with age-related macular degeneration in a case-control study. Arch Ophthalmol. 2007;125(9):1225-32.
Curran Celentano J, Burke JD, Hammond Jr BR. In vivo assessment of retinal carotenoids: macular pigment detection techniques and their impact on monitoring pigment status. J Nutr. 2002;132(3):535S-9S.
Hammond BR, Ciulla TA, Snodderly DM. Macular pigment density is reduced in obese subjects. Investig Ophthalmol Vis Sci. 2002;43:47-50.
Wolf-Schnurrbusch UE, Röösli N, Weyermann E, Heldner MR, Höhne K, Wolf S. Ethnic differences in macular pigment density and distribution. Investig Ophthalmol Vis Sci. 2007;48(8):3783-7.
Bone RA, Landrum JT, Cains A. Optical density spectra of the macular pigment in vivo and in vitro. Vision Res. 1992;2(1):105-10.
Makridaki M, Carden D, Murray IJ. Macular pigment measurement in clinics: controlling the effect of the ageing media. Ophthalmic Physiol Opt. 2009;29:338-44.
Mahley RW, Innerarity TL, Rall SC Jr., Weisgraber KH. Plasma lipoproteins: apolipoprotein structure and function. J Lipid Res. 1984;5(12):1277-94.
Clevidence BA, Bieri JG. Association of carotenoids with human plasma lipoproteins. Meth Enzymol. 1993;214:33-46.
Goulinet S, Chapman MJ. Plasma LDL and HDL subspecies are heterogenous in particle content of tocopherols and oxygenated and hydrocarbon carotenoids. Relevance to oxidative resistance and atherogenesis: Relevance to oxidative resistance and atherogenesis. Arterioscler Thromb Vasc Biol 1997;17:786–96.
Payaponchanok R. Comparison of Macular Pigment Optical Density (MPOD) among Simvastatin 10 mg taking for 6-12 months and non-taking group. Mae Fah Luang Universiy, 2019.
Paworn P. Effect of statins taking to the density of pigment in retina. Mae Fah Luang Universiy, 2018.
Olmedilla-Alonso B, Beltrán-de-Miguel B, Estévez-Santiago R, Cuadrado-Vives C. Markers of lutein and zeaxanthin status in two age groups of men and women: dietary intake, serum concentrations, lipid profile and macular pigment optical density. J Nutr. 2014;13(1):52.